Shijiazhuang Yiling Pharmaceutical (002603) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached ¥4.07 billion, up 0.86% year-over-year; net profit attributable to shareholders was ¥757 million, up 13.28% year-over-year.

• Core business segments include patented innovative Chinese medicines, chemical and biological pharmaceuticals, and health products, with strong R&D and market expansion.

• The company maintains a leading position in cardiovascular and respiratory Chinese medicine markets, with several products listed in national insurance and essential drug catalogs.

• R&D investment was ¥345 million, representing 8.47% of revenue, higher than the industry average.

• No dividend distribution, bonus shares, or capital increase from reserves for the interim period.

Financial highlights

• Operating income: ¥4,074,750,595 (+0.86% YoY).

• Net profit attributable to shareholders: ¥757,298,017 (+13.28% YoY).

• Net profit excluding non-recurring items: ¥731,053,707 (+13.99% YoY).

• Operating cash flow: ¥1,179,763,368 (+41.79% YoY).

• Basic and diluted EPS: ¥0.4533 (+13.27% YoY).

• Gross margin for cardiovascular products: 71.39%; respiratory products: 78.57%.

Outlook and guidance

• The company expects continued growth in innovative Chinese medicine, chemical pharmaceuticals, and health products, leveraging policy support and R&D breakthroughs.

• Ongoing expansion in international markets and product pipeline, with several new drugs in clinical and registration phases.

• Focus on academic-driven marketing and value-based partnerships to enhance brand and channel competitiveness.